ストックスクリーナーアプリを入手
1.45
1.40%
0.02
iBio Inc (IBIO) 最新ニュース
iBio Inc (IBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
iBio Inc (IBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
iBio Inc (IBIO) Balance Sheet - TradingKey
iBio Inc (IBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
iBio Inc (IBIO) Cash Flow - TradingKey
iBio Inc (IBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
iBio Inc (IBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
iBio Inc (IBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
iBio, Inc. Revenue Breakdown – TRADEGATE:0JV0 - TradingView
iBio Inc (IBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
Affinity Asset Advisors LLC Grows Position in iBio, Inc. $IBIO - MarketBeat
IBIO|iBio Inc|Price:1.430|Chg%:+0.030 - TradingKey
iBio Inc (IBIO) Institutional Confidence - TradingKey
Chardan Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
IBIO|iBio Inc|Price:1.395|Chg%:+0.015 - TradingKey
iBio Updates Governance Deadlines for 2026 Annual Meeting - The Globe and Mail
iBio (NYSE: IBIO) schedules 2026 meeting, updates proposal deadlines - Stock Titan
iBio, Inc. (NASDAQ:IBIO) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
iBio (NASDAQ:IBIO) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
iBio Inc. Holds Steady at $1.51 as Biotech Stock Consolidates Near Key LevelsSupply Zone - dars.gov.et
We Think iBio (NASDAQ:IBIO) Can Afford To Drive Business Growth - Sahm
iBio Inc. (IBIO) Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pre‑Revenue PhaseBanking Earnings Report - DonanımHaber
iBio Inc. (IBIO) Retreats 1.85%, Approaching Key Support at $1.51Narrow Range Breakout - DonanımHaber
Price to sales forward of iBio, Inc. – NASDAQ:IBIO - TradingView
Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO) - The Globe and Mail
IBIO Maintained by Chardan Capital -- Price Target Stays at $5.0 - GuruFocus
IBIO News | IBIO INC (NASDAQ:IBIO) - ChartMill
IBIOiBio Inc Latest SEC Filings - Finviz
$IBIO stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
iBio’s IBIO-610 Antibody Achieves 98% Activin E Inhibition and Boosts Fat Loss in Obese Primates, Outperforming Semaglutide Alone 1 - Minichart
iBio Highlights Promising New Preclinical Obesity Antibody Data - TipRanks
Innovative Findings on IBIO-610 from iBio - GuruFocus
iBio (NASDAQ: IBIO) obesity antibody cuts Activin E and spares lean mass - Stock Titan
iBio Inc. announced research results showing that a single administration of the candidate drug IBIO-610 in an obese non-human primate model achieved nearly complete inhibition of active activin E for up to eight weeks. - Bitget
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study - The Manila Times
Single dose of IBIO-610 antibody shows 98% Acti... - Pluang
IBio, Inc.(NasdaqCM: IBIO) added to Russell Microcap Value Benchmark Index - marketscreener.com
IBio, Inc.(NasdaqCM: IBIO) added to Russell 3000E Index - marketscreener.com
IBio, Inc.(NasdaqCM: IBIO) added to Russell Microcap Index - marketscreener.com
iBio Inc. (IBIO) Surges Over 5% on Renewed Biotech Interest – Key Levels in FocusNegative Gamma - dars.gov.et
Enterprise value to revenue forward of iBio, Inc. – NASDAQ:IBIO - TradingView
Price to book forward of iBio, Inc. – NASDAQ:IBIO - TradingView
Enterprise value to EBIT forward of iBio, Inc. – NASDAQ:IBIO - TradingView
How iBio aims to stand out in obesity by targeting ‘both sides of the equation’ for antibody discovery - Fierce Biotech
iBio, Inc. Actuals & Estimates (NASDAQ:IBIO) - TradingView
0JV0 Forecast — Price Target — Prediction for 2027 - TradingView
IBIO Forecast — Price Target — Prediction for 2027 - TradingView
iBio Inc. (IBIO) Slips 1.23% — Stock Tests Support Zone Amid Low VolumeTrend Reversal Picks - dars.gov.et
iBio Inc. Q1 2026 Earnings: EPS Beat Mitigates Broader Market ConcernsProfit Inflection Point - dars.gov.et
Top iBio (IBIO) Competitors 2026 - MarketBeat
IBIO Q1 2026 Earnings: Narrowed Loss Per Share Exceeds Expectations, Stock Responds PositivelyPerformance Review - DonanımHaber
iBio Inc (IBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IBIO Q1 2026 Earnings: EPS Miss Amidst Continued R&D InvestmentAdjusted Earnings Analysis - dars.gov.et
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):